Is PFE a buy, hold, or sell?
PFE carries a valuation grade of Buy. At a trailing P/E of 19.2, the stock trades at a 13% discount to the Healthcare sector median of 22.0x. Our discounted cash flow model produces an intrinsic range of $33–$57 — implying a +78% margin of safety at the current price of $25.21. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 3.9% earnings surprise. Analyst estimate revisions are trending upward.
What are PFE's key risk factors?
With a beta of 0.29, PFE exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -8.0% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 0.8% of total portfolio loss in the worst 5% of months. Net margins of 11.8% fall below the Healthcare sector average of 18%, suggesting margin pressure. The balance sheet is conservatively leveraged at 72% debt-to-equity.
At 0.39, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 26.2% exceeds realized volatility of 18.8% by 7 points, suggesting options are pricing in elevated risk. Insider transactions show net buying of $70.9M over the trailing period, a signal often associated with management confidence. Short interest is low at 2.9% of float, suggesting limited bearish conviction.
How does PFE fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — PFE carries a beta of 0.29, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, PFE shows the strongest co-movement with BMY (0.60), MRK (0.57), AZN (0.51). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The PFE analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning PFE’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
